(ERF) Eurofins Scientific SE - Ratings and Ratios
Testing, Laboratory, Services, Analytical, Biotechnology
ERF EPS (Earnings per Share)
ERF Revenue
Description: ERF Eurofins Scientific SE
Eurofins Scientific SE is a global provider of analytical testing and laboratory services, operating in various sectors including agroscience, biopharma, clinical diagnostics, consumer products, environmental testing, and food and feed testing. The companys diverse service portfolio includes testing, certification, inspection, training, and advisory services.
From a business perspective, Eurofins Scientific SE has a strong presence in the biotechnology industry, with a GICS sub-industry classification. The companys services cater to a wide range of industries, including pharmaceuticals, food and feed, environmental monitoring, and consumer goods. Key performance indicators (KPIs) to watch include revenue growth, EBITDA margins, and return on equity (RoE), which currently stands at 10.82%. The companys ability to expand its services through strategic acquisitions and organic growth will be crucial in driving future performance.
To evaluate Eurofins Scientific SEs stock performance, we can examine key metrics such as the price-to-earnings (P/E) ratio, which is currently at 28.84, and the forward P/E ratio, which is 15.22. The stocks market capitalization is approximately 10.84 billion EUR. Other relevant KPIs include the dividend yield, payout ratio, and enterprise value-to-EBITDA (EV/EBITDA) ratio. Analyzing these metrics will provide insights into the companys valuation and potential for future growth.
From a technical analysis perspective, Eurofins Scientific SEs stock price is currently at 61.36 EUR, with a 20-day simple moving average (SMA) of 60.46 EUR and a 50-day SMA of 58.85 EUR, indicating a positive trend. The stocks average true range (ATR) is 0.87 EUR, representing a volatility of 1.42%. Further analysis of the stocks chart patterns, trends, and momentum indicators will help identify potential trading opportunities.
ERF Stock Overview
| Market Cap in USD | 13,395m |
| Sub-Industry | Biotechnology |
| IPO / Inception |
ERF Stock Ratings
| Growth Rating | 19.3% |
| Fundamental | 70.2% |
| Dividend Rating | 7.83% |
| Return 12m vs S&P 500 | 1.41% |
| Analyst Rating | - |
ERF Dividends
| Dividend Yield 12m | 1.05% |
| Yield on Cost 5y | 0.97% |
| Annual Growth 5y | -7.40% |
| Payout Consistency | 85.9% |
| Payout Ratio | 26.4% |
ERF Growth Ratios
| Growth Correlation 3m | 52.3% |
| Growth Correlation 12m | 78.8% |
| Growth Correlation 5y | -75.7% |
| CAGR 5y | 2.90% |
| CAGR/Max DD 3y | 0.08 |
| CAGR/Mean DD 3y | 0.15 |
| Sharpe Ratio 12m | 0.14 |
| Alpha | 0.34 |
| Beta | 0.000 |
| Volatility | 28.33% |
| Current Volume | 185.3k |
| Average Volume 20d | 191.5k |
| Stop Loss | 60.8 (-3.2%) |
| Signal | -0.18 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (503.1m TTM) > 0 and > 6% of Revenue (6% = 628.0m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 4.22pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 5.10% (prev 9.67%; Δ -4.57pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 2.01b > Net Income 503.1m (YES >=105%, WARN >=100%) |
| Net Debt (3.36b) to EBITDA (2.17b) ratio: 1.55 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.26 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (188.5m) change vs 12m ago -4.61% (target <= -2.0% for YES) |
| Gross Margin 14.42% (prev 12.63%; Δ 1.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 97.48% (prev 89.74%; Δ 7.73pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.20 (EBITDA TTM 2.17b / Interest Expense TTM 221.7m) >= 6 (WARN >= 3) |
Altman Z'' 2.78
| (A) 0.05 = (Total Current Assets 2.62b - Total Current Liabilities 2.09b) / Total Assets 10.59b |
| (B) 0.27 = Retained Earnings (Balance) 2.81b / Total Assets 10.59b |
| (C) 0.11 = EBIT TTM 1.15b / Avg Total Assets 10.74b |
| (D) 0.82 = Book Value of Equity 4.86b / Total Liabilities 5.91b |
| Total Rating: 2.78 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 70.17
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 7.45% = 3.73 |
| 3. FCF Margin 10.46% = 2.62 |
| 4. Debt/Equity 0.89 = 2.12 |
| 5. Debt/Ebitda 1.89 = 0.21 |
| 6. ROIC - WACC (= 5.46)% = 6.83 |
| 7. RoE 9.84% = 0.82 |
| 8. Rev. Trend 15.42% = 1.16 |
| 9. EPS Trend 13.76% = 0.69 |
What is the price of ERF shares?
Over the past week, the price has changed by -0.25%, over one month by -6.77%, over three months by +3.53% and over the past year by +20.20%.
Is Eurofins Scientific SE a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ERF is around 61.72 EUR . This means that ERF is currently overvalued and has a potential downside of -1.69%.
Is ERF a buy, sell or hold?
What are the forecasts/targets for the ERF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 64.4 | 2.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 66.5 | 5.9% |
ERF Fundamental Data Overview
Market Cap EUR = 11.34b (11.34b EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = 753.3m EUR (last quarter)
P/E Trailing = 28.1145
P/E Forward = 14.7059
P/S = 1.5868
P/B = 2.4527
P/EG = 0.6098
Beta = 0.695
Revenue TTM = 10.47b EUR
EBIT TTM = 1.15b EUR
EBITDA TTM = 2.17b EUR
Long Term Debt = 3.58b EUR (from longTermDebt, last quarter)
Short Term Debt = 538.4m EUR (from shortTermDebt, last quarter)
Debt = 4.11b EUR (Calculated: Short Term 538.4m + Long Term 3.58b)
Net Debt = 3.36b EUR (from netDebt column, last quarter)
Enterprise Value = 14.70b EUR (11.34b + Debt 4.11b - CCE 753.3m)
Interest Coverage Ratio = 5.20 (Ebit TTM 1.15b / Interest Expense TTM 221.7m)
FCF Yield = 7.45% (FCF TTM 1.10b / Enterprise Value 14.70b)
FCF Margin = 10.46% (FCF TTM 1.10b / Revenue TTM 10.47b)
Net Margin = 4.81% (Net Income TTM 503.1m / Revenue TTM 10.47b)
Gross Margin = 14.42% ((Revenue TTM 10.47b - Cost of Revenue TTM 8.96b) / Revenue TTM)
Tobins Q-Ratio = 3.03 (Enterprise Value 14.70b / Book Value Of Equity 4.86b)
Interest Expense / Debt = 1.67% (Interest Expense 68.6m / Debt 4.11b)
Taxrate = 26.88% (149.1m / 554.6m)
NOPAT = 842.8m (EBIT 1.15b * (1 - 26.88%))
Current Ratio = 1.26 (Total Current Assets 2.62b / Total Current Liabilities 2.09b)
Debt / Equity = 0.89 (Debt 4.11b / last Quarter total Stockholder Equity 4.64b)
Debt / EBITDA = 1.89 (Net Debt 3.36b / EBITDA 2.17b)
Debt / FCF = 3.76 (Debt 4.11b / FCF TTM 1.10b)
Total Stockholder Equity = 5.11b (last 4 quarters mean)
RoA = 4.75% (Net Income 503.1m, Total Assets 10.59b )
RoE = 9.84% (Net Income TTM 503.1m / Total Stockholder Equity 5.11b)
RoCE = 13.26% (Ebit 1.15b / (Equity 5.11b + L.T.Debt 3.58b))
RoIC = 10.21% (NOPAT 842.8m / Invested Capital 8.26b)
WACC = 4.74% (E(11.34b)/V(15.45b) * Re(6.02%)) + (D(4.11b)/V(15.45b) * Rd(1.67%) * (1-Tc(0.27)))
Shares Correlation 3-Years: -82.19 | Cagr: -0.54%
Discount Rate = 6.02% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 78.26% ; FCFE base≈924.0m ; Y1≈922.1m ; Y5≈974.4m
Fair Price DCF = 97.07 (DCF Value 17.24b / Shares Outstanding 177.6m; 5y FCF grow -0.83% → 3.0% )
EPS Correlation: 13.76 | EPS CAGR: 211.2% | SUE: -4.0 | # QB: 0
Revenue Correlation: 15.42 | Revenue CAGR: 4.09% | SUE: 0.0 | # QB: 0